Schall Law Firm Investigates Abivax Over Obefazimod Trial Disclosures

GlobeNewswire··Read original
3▲0 ▼1Impact / 5
Summary · why it matters

The Schall Law Firm has launched an investigation into Abivax S.A. for potential securities law violations. The inquiry centers on whether the company made false or misleading statements or failed to disclose material information regarding its Phase 3 ABTECT trial for obefazimod, which revealed rare malignancy cases in its results. Following this news, Abivax shares fell sharply on June 2, 2026. Investors who suffered losses are encouraged to contact the firm.

Impact on assets 1

Biotech & Genomic Medicine▼
Abivax SA
ABVX
▼ NegativeRegulationrelevance

Investigation for potential securities law violations related to undisclosed malignancy cases in obefazimod trial.